Literature DB >> 19816914

Semi-Automated method of analysis of horizontal histological sections of skin for objective evaluation of fractional devices.

Brian D Zelickson1, Susan E Walgrave, Munir Yahya H Al-Arashi, Gregory B Altshuler, Ilya V Yaroslavsky, James J Childs, Rich H Cohen, Andrei V Erofeev, Erminaldo F Depina, Mikhail Z Smirnov, David A Kist, David R Tabatadze.   

Abstract

BACKGROUND AND
OBJECTIVE: The treatment of skin with fractional devices creates columns of micro-ablation or micro-denaturation depending on the device. Since the geometric profiles of thermal damage depend on the treatment parameters or physical properties of the treated tissue, the size of these columns may vary from a few microns to a few millimeters. For objective evaluation of the damage profiles generated by fractional devices, this report describes an innovative and efficient method of processing and evaluating horizontal sections of skin using a novel software program.
MATERIALS AND METHODS: Ex vivo porcine skin was treated with the Lux1540/10, Lux1540 Zoom and Lux2940 with 500 optics. Horizontal (radial) sections of biopsies were obtained and processed with H&E and NBTC staining. Digital images of the histologic sections were taken in either transmission or reflection illumination and were processed using the SAFHIR program.
RESULTS: NBTC- and H&E-stained horizontal sections of ex vivo skin treated with ablative and non-ablative fractional devices were obtained. Geometric parameters, such as depth, diameter, and width of the coagulated layer (if applicable), and micro-columns of thermal damage, were evaluated using the SAFHIR software. The feasibility of objective comparison of the performance of two different fractional devices was demonstrated.
CONCLUSION: The proposed methodology provides a comprehensive, objective, and efficient approach for the comparison of various fractional devices. Correlation of device settings with the objective dimensions of post-treatment damage profiles serve as a powerful tool for the prediction and modulation of clinical response. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19816914     DOI: 10.1002/lsm.20843

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  6 in total

1.  Multisource, Phase-controlled Radiofrequency for Treatment of Skin Laxity: Correlation Between Clinical and In-vivo Confocal Microscopy Results and Real-Time Thermal Changes.

Authors:  Josefina Royo de la Torre; Javier Moreno-Moraga; Estefania Muñoz; Paloma Cornejo Navarro
Journal:  J Clin Aesthet Dermatol       Date:  2011-01

2.  Lesion dimensions following ablative fractional laser treatment in non-melanoma skin cancer and premalignant lesions.

Authors:  Katrine Togsverd-Bo; Uwe Paasch; Christina S Haak; Merete Haedersdal
Journal:  Lasers Med Sci       Date:  2011-10-01       Impact factor: 3.161

3.  Histological evaluation of vertical laser channels from ablative fractional resurfacing: an ex vivo pig skin model.

Authors:  Christina Skovbølling Haak; Monica Illes; Uwe Paasch; Merete Hædersdal
Journal:  Lasers Med Sci       Date:  2010-08-28       Impact factor: 3.161

4.  In vivo optical monitoring of transcutaneous delivery of calcium carbonate microcontainers.

Authors:  Elina A Genina; Yulia I Svenskaya; Irina Yu Yanina; Leonid E Dolotov; Nikita A Navolokin; Alexey N Bashkatov; Georgy S Terentyuk; Alla B Bucharskaya; Galina N Maslyakova; Dmitry A Gorin; Valery V Tuchin; Gleb B Sukhorukov
Journal:  Biomed Opt Express       Date:  2016-05-03       Impact factor: 3.732

5.  Histological validity and clinical evidence for use of fractional lasers for acne scars.

Authors:  Kabir Sardana; Vijay K Garg; Pooja Arora; Nita Khurana
Journal:  J Cutan Aesthet Surg       Date:  2012-04

6.  Percutaneous bone marrow transplantation using fractional ablative Erbium:YAG laser.

Authors:  Luis Rodriguez-Menocal; Marcela Salgado; Stephen Davis; Jill Waibel; Arsalan Shabbir; Audrey Cox; Evangelos V Badiavas
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.